Christopher E. Starr, MD, FACS

Christopher E. Starr, MD, FACS, highlights diagnostic gaps in dry eye, emphasizing neuropathic corneal pain and reviewing emerging therapies and pipeline treatments in ocular surface disease.

Expanded guidance incorporates advanced diagnostics and reinforces treatment of conditions such as Demodex blepharitis and neuropathic pain, explains Christopher E. Starr, MD, FACS.

Ophthalmologists weigh in on evolving diagnostic tools, emerging therapies, and practical approaches for managing today’s most challenging ocular-surface cases.

A panelist discusses how treating demodex blepharitis with Lotilaner not only eliminates the anterior blepharitis symptoms but also improves meibomian gland function, with low recurrence rates after treatment and significant benefits for patient comfort and quality of life.

A panelist discusses how demodex blepharitis frequently co-occurs with other ocular surface conditions in younger patients, as illustrated by a 35-year-old contact lens wearer who presented with recurrent styes, contact lens intolerance, and a history of rosacea.

A panelist discusses how treating ocular surface disease and demodex blepharitis before cataract surgery led to improved refractive measurements, resolved corneal staining, and enabled successful multifocal IOL implantation in a patient who had previously shown irregularly irregular topography patterns.

A panelist discusses how demodex blepharitis presents with distinctive symptoms like eyelash itching, colorettes at the base of lashes, and can significantly affect pre-surgical cataract measurements, requiring treatment before proceeding with surgery.